| Name | Brilliant blue G-250 |
| Description | Brilliant blue G-250 (Acid blue 90, Coomassie Brilliant Blue G) is an antagonist of the P2X7 purinergic receptor. |
| In vitro | Brilliant Blue G-250 is used for protein staining after polyacrylamide gel electrophoresis
Instructions
1. The protein electrophoresis gel is fixed in 50% methanol, 10% acetic acid, and 40% aqueous solution, and shaken at a low speed on a horizontal shaker for 30 min to overnight.
2. Remove the fixative and replace with 0.25% Coomassie Brilliant Blue R250 staining solution (0.25% R250 dissolved in 50% methanol, 10% acetic acid, and 40% aqueous solution) to completely cover the gel and stain for 2-4 h. Until the gel is stained uniformly blue.
Note: When the gel is invisible to the naked eye in the staining solution, it means that the staining is complete, otherwise the gel area looks lighter in color compared to the dark staining solution.
3. Place the gel back in 5% methanol, 7.5% acetic acid, and 87.5% aqueous solution for 4-24 h for decolorization. The protein bands will be visible after about 1-2 hours, and the destaining process will not be completed until the background becomes transparent. The destaining solution can be changed 2-4 times in the middle.
4. Store the gel in 7% acetic acid. It can also be stored in water or dry.
The above information is based on published literature. Experimental procedures should be appropriately modified to meet specific research demands. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween-80+45% Saline : 0.5 mg/mL (0.59 mM), Sonication is recommended.
DMSO : 8.55 mg/mL (10.01 mM), Sonication is recommended.
|
| Keywords | SDS-PAGE | P2XReceptor | P2X7 | P2X Receptor | P2×7R | NLRP3 inflammasome | Inhibitor | inhibit | dye | Brilliant blue G-250 | Brilliant blue G250 | Brilliant blue G 250 | Bradford protein |
| Inhibitors Related | Gefapixant citrate | Eperisone hydrochloride | Aurintricarboxylic acid | Sodium metatungstate | NP-1815-PX | (E/Z)-Sivopixant | PSB-12062 | ATP disodium salt | Oxatomide | Ivermectin | Lappaconitine | Paroxetine |
| Related Compound Libraries | Failed Clinical Trials Compound Library | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Anti-Cancer Approved Drug Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library |
United States
